Anaplastic oligodendroglial tumors: Refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402

Caterina Giannini, Peter C. Burger, Brian A. Berkey, J. Gregory Cairncross, Robert Brian Jenkins, Minesh Mehta, Walter J. Curran, Ken Aldape

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

Intergroup Radiation Therapy Oncology Group Trial 9402 study, a phase III trial of chemotherapy plus radiotherapy (PCV-plus-RT) vs. radiotherapy alone for pure and mixed anaplastic oligodendroglioma confirmed the prognostic significance of 1p 19q deletion and showed that only progression-free survival (PFS) was prolonged in PCV-plus-RT-treated patients and only in association with 1p 19q deletion. We reviewed tumor histopathology, separating 115 tumors deemed to be classic for oligodendroglioma (CFO) from 132 lacking classic features of oligodendroglioma (NCFO) and evaluated the relationship of histopathology and 1p 19q status to treatment and outcome. The study disclosed: (i) overall survival (OS) of patients with CFO was significantly longer than for patients with NCFO (P < 0.0001) and was not affected by necrosis. Median OS for CFO patients with and without necrosis was 6.6 and 6.3 years (OS log-rank P = not significant), respectively, in contrast to NCFO showing 1.9 and 3.3 years respectively (OS log-rank P = 0.014). (ii) Classic oligodendroglial morphology was highly associated with 1p 19q deletion, present in 80% of CFO and only in 13% of NCFO. (iii) On multivariate analysis, both classic oligodendroglial morphology and 1p 19q deletion remained significantly associated with PFS and OS. (iv) Patients with CFO treated with PCV-plus-RT showed a trend toward increased survival compared with CFO treated with RT (P = 0.08). Median OS was not reached in the PCV-plus-RT group and was 6.3 years in RT group. These findings suggest that classic oligodendroglial morphology combined with 1p 19q deletion may in the future be predictive of chemotherapeutic response and survival.

Original languageEnglish (US)
Pages (from-to)360-369
Number of pages10
JournalBrain Pathology
Volume18
Issue number3
DOIs
StatePublished - Jul 2008

Fingerprint

Oligodendroglioma
Radiation Oncology
Radiotherapy
Survival
Neoplasms
Disease-Free Survival
Necrosis
Monosomy 1p Chromosome 1
Multivariate Analysis
Drug Therapy

Keywords

  • 1p 19q deletion
  • Anaplastic oligoastrocytoma
  • Anaplastic oligodendroglioma

ASJC Scopus subject areas

  • Neuroscience(all)
  • Pathology and Forensic Medicine

Cite this

Anaplastic oligodendroglial tumors : Refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. / Giannini, Caterina; Burger, Peter C.; Berkey, Brian A.; Cairncross, J. Gregory; Jenkins, Robert Brian; Mehta, Minesh; Curran, Walter J.; Aldape, Ken.

In: Brain Pathology, Vol. 18, No. 3, 07.2008, p. 360-369.

Research output: Contribution to journalArticle

Giannini, Caterina ; Burger, Peter C. ; Berkey, Brian A. ; Cairncross, J. Gregory ; Jenkins, Robert Brian ; Mehta, Minesh ; Curran, Walter J. ; Aldape, Ken. / Anaplastic oligodendroglial tumors : Refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. In: Brain Pathology. 2008 ; Vol. 18, No. 3. pp. 360-369.
@article{96f2fcd540f640b4b19aff77422f9b6d,
title = "Anaplastic oligodendroglial tumors: Refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402",
abstract = "Intergroup Radiation Therapy Oncology Group Trial 9402 study, a phase III trial of chemotherapy plus radiotherapy (PCV-plus-RT) vs. radiotherapy alone for pure and mixed anaplastic oligodendroglioma confirmed the prognostic significance of 1p 19q deletion and showed that only progression-free survival (PFS) was prolonged in PCV-plus-RT-treated patients and only in association with 1p 19q deletion. We reviewed tumor histopathology, separating 115 tumors deemed to be classic for oligodendroglioma (CFO) from 132 lacking classic features of oligodendroglioma (NCFO) and evaluated the relationship of histopathology and 1p 19q status to treatment and outcome. The study disclosed: (i) overall survival (OS) of patients with CFO was significantly longer than for patients with NCFO (P < 0.0001) and was not affected by necrosis. Median OS for CFO patients with and without necrosis was 6.6 and 6.3 years (OS log-rank P = not significant), respectively, in contrast to NCFO showing 1.9 and 3.3 years respectively (OS log-rank P = 0.014). (ii) Classic oligodendroglial morphology was highly associated with 1p 19q deletion, present in 80{\%} of CFO and only in 13{\%} of NCFO. (iii) On multivariate analysis, both classic oligodendroglial morphology and 1p 19q deletion remained significantly associated with PFS and OS. (iv) Patients with CFO treated with PCV-plus-RT showed a trend toward increased survival compared with CFO treated with RT (P = 0.08). Median OS was not reached in the PCV-plus-RT group and was 6.3 years in RT group. These findings suggest that classic oligodendroglial morphology combined with 1p 19q deletion may in the future be predictive of chemotherapeutic response and survival.",
keywords = "1p 19q deletion, Anaplastic oligoastrocytoma, Anaplastic oligodendroglioma",
author = "Caterina Giannini and Burger, {Peter C.} and Berkey, {Brian A.} and Cairncross, {J. Gregory} and Jenkins, {Robert Brian} and Minesh Mehta and Curran, {Walter J.} and Ken Aldape",
year = "2008",
month = "7",
doi = "10.1111/j.1750-3639.2008.00129.x",
language = "English (US)",
volume = "18",
pages = "360--369",
journal = "Brain Pathology",
issn = "1015-6305",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Anaplastic oligodendroglial tumors

T2 - Refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402

AU - Giannini, Caterina

AU - Burger, Peter C.

AU - Berkey, Brian A.

AU - Cairncross, J. Gregory

AU - Jenkins, Robert Brian

AU - Mehta, Minesh

AU - Curran, Walter J.

AU - Aldape, Ken

PY - 2008/7

Y1 - 2008/7

N2 - Intergroup Radiation Therapy Oncology Group Trial 9402 study, a phase III trial of chemotherapy plus radiotherapy (PCV-plus-RT) vs. radiotherapy alone for pure and mixed anaplastic oligodendroglioma confirmed the prognostic significance of 1p 19q deletion and showed that only progression-free survival (PFS) was prolonged in PCV-plus-RT-treated patients and only in association with 1p 19q deletion. We reviewed tumor histopathology, separating 115 tumors deemed to be classic for oligodendroglioma (CFO) from 132 lacking classic features of oligodendroglioma (NCFO) and evaluated the relationship of histopathology and 1p 19q status to treatment and outcome. The study disclosed: (i) overall survival (OS) of patients with CFO was significantly longer than for patients with NCFO (P < 0.0001) and was not affected by necrosis. Median OS for CFO patients with and without necrosis was 6.6 and 6.3 years (OS log-rank P = not significant), respectively, in contrast to NCFO showing 1.9 and 3.3 years respectively (OS log-rank P = 0.014). (ii) Classic oligodendroglial morphology was highly associated with 1p 19q deletion, present in 80% of CFO and only in 13% of NCFO. (iii) On multivariate analysis, both classic oligodendroglial morphology and 1p 19q deletion remained significantly associated with PFS and OS. (iv) Patients with CFO treated with PCV-plus-RT showed a trend toward increased survival compared with CFO treated with RT (P = 0.08). Median OS was not reached in the PCV-plus-RT group and was 6.3 years in RT group. These findings suggest that classic oligodendroglial morphology combined with 1p 19q deletion may in the future be predictive of chemotherapeutic response and survival.

AB - Intergroup Radiation Therapy Oncology Group Trial 9402 study, a phase III trial of chemotherapy plus radiotherapy (PCV-plus-RT) vs. radiotherapy alone for pure and mixed anaplastic oligodendroglioma confirmed the prognostic significance of 1p 19q deletion and showed that only progression-free survival (PFS) was prolonged in PCV-plus-RT-treated patients and only in association with 1p 19q deletion. We reviewed tumor histopathology, separating 115 tumors deemed to be classic for oligodendroglioma (CFO) from 132 lacking classic features of oligodendroglioma (NCFO) and evaluated the relationship of histopathology and 1p 19q status to treatment and outcome. The study disclosed: (i) overall survival (OS) of patients with CFO was significantly longer than for patients with NCFO (P < 0.0001) and was not affected by necrosis. Median OS for CFO patients with and without necrosis was 6.6 and 6.3 years (OS log-rank P = not significant), respectively, in contrast to NCFO showing 1.9 and 3.3 years respectively (OS log-rank P = 0.014). (ii) Classic oligodendroglial morphology was highly associated with 1p 19q deletion, present in 80% of CFO and only in 13% of NCFO. (iii) On multivariate analysis, both classic oligodendroglial morphology and 1p 19q deletion remained significantly associated with PFS and OS. (iv) Patients with CFO treated with PCV-plus-RT showed a trend toward increased survival compared with CFO treated with RT (P = 0.08). Median OS was not reached in the PCV-plus-RT group and was 6.3 years in RT group. These findings suggest that classic oligodendroglial morphology combined with 1p 19q deletion may in the future be predictive of chemotherapeutic response and survival.

KW - 1p 19q deletion

KW - Anaplastic oligoastrocytoma

KW - Anaplastic oligodendroglioma

UR - http://www.scopus.com/inward/record.url?scp=44649088238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44649088238&partnerID=8YFLogxK

U2 - 10.1111/j.1750-3639.2008.00129.x

DO - 10.1111/j.1750-3639.2008.00129.x

M3 - Article

C2 - 18371182

AN - SCOPUS:44649088238

VL - 18

SP - 360

EP - 369

JO - Brain Pathology

JF - Brain Pathology

SN - 1015-6305

IS - 3

ER -